NanoString Announces Collaboration with National Cancer Institute to Improve Cancer Immunotherapy Biomarker …GlobeNewswire (press release)SEATTLE, June 04, 2018 (GLOBE NEWSWIRE) — NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life scien… Continue reading
Drug Target Review |
CRISPR approach could limit toxicity of CAR-T therapy in AML
Drug Target Review A new approach may provide a new path towards treating acute myeloid leukaemia (AML) with CAR-T cells. To treat AML, investigators have to target a specific protein – CD33 – that’s also expressed on healthy cells, meaning the therapy cannot attack the … |
News-Medical.net |
Stem Cell Therapy for Alzheimer’s
News-Medical.net Stem cell treatments target to replace the damaged cells with healthy stem cells which can grow on their own, hence, creating new healthy brain cells. Because the transplant is usually autologous (using patient’s own body cells) in nature, there are … Taking Stem Cells to the BankPain News Network Global and Chinese Autologous Stem Cell Market Report by Manufacturers, Opportunities, Challenges, Drivers, Growth …Business Investor Market Analysis of Stem Cell Therapy for Diabetes and Related Conditions | Key Players Analysis and Forecast to 2021Exclusive Reportage Clean Technology –Expert Consulting –Technical Progress all 63 news articles » |
Tech Times |
Immunotherapy Drug Keytruda Halts ‘Untreatable’ Prostate Cancer In Some Men
Tech Times Earlier trials on using immunotherapy in prostate cancer have been unsuccessful. The latest trial, results of which were presented this weekend at the American Society of Clinical Oncology Meeting in Chicago, examined the genetics of tumors and found … Immunotherapy could stop prostate cancer spreading, trial showsThe Guardian Immunotherapy could treat prostate cancerThe European Scientist ‘Untreatable’ prostate cancer halted in some men by new immunotherapy drug, trial findsThe Independent Forbes –BBC News –NHK WORLD all 52 news articles » |
|
ASCO18: Celgene makes its case as CAR–T rival in lymphoma
BioPharma Dive Celgene’s experimental cell therapy JCAR017, or liso-cel, could prove competitive in lymphoma with already on-market treatments from Gilead and Novartis, suggest updated clinical results presented Sunday at the annual meeting of the American Society of … |